111 related articles for article (PubMed ID: 35449312)
1. Comprehensive genetic characterization of rectal cancer in a large cohort of Japanese patients: differences according to tumor location.
Hino H; Shiomi A; Hatakeyama K; Kagawa H; Manabe S; Yamaoka Y; Nagashima T; Ohshima K; Urakami K; Akiyama Y; Yamaguchi K
J Gastroenterol; 2022 Jul; 57(7):476-485. PubMed ID: 35449312
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the localization of rectal carcinomas according to the general rules of the Japanese classification of colorectal carcinoma (JCCRC) and Western guidelines.
Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G
Surg Today; 2017 Sep; 47(9):1086-1093. PubMed ID: 28271342
[TBL] [Abstract][Full Text] [Related]
3. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
[TBL] [Abstract][Full Text] [Related]
4.
Sideris M; Moorhead J; Diaz-Cano S; Haji A; Papagrigoriadis S
Anticancer Res; 2017 Mar; 37(3):1349-1357. PubMed ID: 28314302
[TBL] [Abstract][Full Text] [Related]
5. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes.
Loree JM; Pereira AAL; Lam M; Willauer AN; Raghav K; Dasari A; Morris VK; Advani S; Menter DG; Eng C; Shaw K; Broaddus R; Routbort MJ; Liu Y; Morris JS; Luthra R; Meric-Bernstam F; Overman MJ; Maru D; Kopetz S
Clin Cancer Res; 2018 Mar; 24(5):1062-1072. PubMed ID: 29180604
[No Abstract] [Full Text] [Related]
6. KRAS mutation status concordance between the primary tumor and the corresponding metastasis in patients with rectal cancer.
Jo P; Bernhardt M; Nietert M; König A; Azizian A; Schirmer MA; Grade M; Kitz J; Reuter-Jessen K; Ghadimi M; Ströbel P; Schildhaus HU; Gaedcke J
PLoS One; 2020; 15(10):e0239806. PubMed ID: 33002027
[TBL] [Abstract][Full Text] [Related]
7. Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
Sclafani F; Wilson SH; Cunningham D; Gonzalez De Castro D; Kalaitzaki E; Begum R; Wotherspoon A; Capdevila J; Glimelius B; Roselló S; Thomas J; Tait D; Brown G; Oates J; Chau I
Int J Cancer; 2020 Jan; 146(1):94-102. PubMed ID: 31199501
[TBL] [Abstract][Full Text] [Related]
8. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
[TBL] [Abstract][Full Text] [Related]
9. KRAS Mutant Status, p16 and β-catenin Expression May Predict Local Recurrence in Patients Who Underwent Transanal Endoscopic Microsurgery (TEMS) for Stage I Rectal Cancer.
Sideris M; Moorhead J; Diaz-Cano S; Bjarnason I; Haji A; Papagrigoriadis S
Anticancer Res; 2016 Oct; 36(10):5315-5324. PubMed ID: 27798894
[TBL] [Abstract][Full Text] [Related]
10. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
11. External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS.
Alwers E; Bläker H; Walter V; Jansen L; Kloor M; Arnold A; Sieber-Frank J; Herpel E; Tagscherer KE; Roth W; Chang-Claude J; Brenner H; Hoffmeister M
BMC Cancer; 2019 Jul; 19(1):681. PubMed ID: 31296182
[TBL] [Abstract][Full Text] [Related]
12. Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.
Maus MK; Hanna DL; Stephens CL; Astrow SH; Yang D; Grimminger PP; Loupakis F; Hsiang JH; Zeger G; Wakatsuki T; Barzi A; Lenz HJ
Pharmacogenomics J; 2015 Aug; 15(4):354-62. PubMed ID: 25532759
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer.
Kohonen-Corish MR; Tseung J; Chan C; Currey N; Dent OF; Clarke S; Bokey L; Chapuis PH
Int J Cancer; 2014 Jun; 134(12):2820-8. PubMed ID: 24259266
[TBL] [Abstract][Full Text] [Related]
14. Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery.
Derbel O; Wang Q; Desseigne F; Rivoire M; Meeus P; Peyrat P; Stella M; Martel-Lafay I; Lemaistre AI; de La Fouchardière C
BMC Cancer; 2013 Apr; 13():200. PubMed ID: 23617638
[TBL] [Abstract][Full Text] [Related]
15. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
17. Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer.
Mochizuki K; Kudo SE; Kato K; Kudo K; Ogawa Y; Kouyama Y; Takashina Y; Ichimasa K; Tobo T; Toshima T; Hisamatsu Y; Yonemura Y; Masuda T; Miyachi H; Ishida F; Nemoto T; Mimori K
PLoS One; 2022; 17(10):e0273566. PubMed ID: 36264865
[TBL] [Abstract][Full Text] [Related]
18. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
[TBL] [Abstract][Full Text] [Related]
19. The interplay of KRAS mutational status with tumor laterality in non-metastatic colorectal cancer: An international, multi-institutional study in patients with known KRAS, BRAF, and MSI status.
Kamphues C; Kadowaki S; Amini N; van den Berg I; Wang J; Andreatos N; Sakamoto Y; Ogura T; Kakuta M; Pikouli A; Geka D; Daitoku N; Theochari M; Buettner S; Akiyama T; Antoniou E; Pikoulis E; Theodoropoulos G; Imai K; Ijzermans JNM; Margonis GA; Akagi K; Kreis ME
J Surg Oncol; 2021 Mar; 123(4):1005-1014. PubMed ID: 33368279
[TBL] [Abstract][Full Text] [Related]
20. CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification.
Pilati C; Taieb J; Balogoun R; Marisa L; de Reyniès A; Laurent-Puig P
Ann Oncol; 2017 May; 28(5):1032-1035. PubMed ID: 28328000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
